http://www.cnr.it/ontology/cnr/individuo/prodotto/ID26422
High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA (Articolo in rivista)
- Type
- Label
- High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA (Articolo in rivista) (literal)
- Anno
- 2003-01-01T00:00:00+01:00 (literal)
- Alternative label
Vacek MM, Ma H, Gemignani F, Lacerra G, Kafri T, Kole R. (2003)
High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA
in Blood
(literal)
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
- Vacek MM, Ma H, Gemignani F, Lacerra G, Kafri T, Kole R. (literal)
- Pagina inizio
- Pagina fine
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
- Rivista
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#descrizioneSinteticaDelProdotto
- In questo lavoro si dimostra che virus lentovirali con snRNA modificato (U7.623), contenente una sequenza antisenso a regione di siti di splicing anomali che causano inattivazione del gene beta globinico, trasfettati in cellule HeLa che esprimono mutanti talassemici e soprattutto in cellule staminali ematopoietiche da pazienti con difetti di splicing a carico dei geni beta globinici, corregge il difetto talassemico portando ad un aumentato livello del mRNA beta globinico correttamente processato e alla sintesi della proteina. (literal)
- Note
- ISI Web of Science (WOS) (literal)
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
- 1 University of North Caroline,Chapell Hill, USA; 2 IARC, Lyon, France; 3 Istituto di Genetica e Biofisica - CNR, Italy. (literal)
- Titolo
- High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA (literal)
- Abstract
- Mutations at nucleotides 654, 705, or 745 in intron 2 of the human beta-globin gene activate aberrant 3' and 5' splice sites within the intron and prevent correct splicing of beta-globin pre-mRNA, resulting in inhibition of beta-globin synthesis and in consequence beta-thalassemia. Transfection of HeLa cells expressing the 3 thalassemic mutants with modified U7 snRNA (U7.623), containing a sequence antisense to a region between the aberrant splice sites, reduced the incorrect splicing of pre-mRNA and led to increased levels of the correctly spliced beta-globin mRNA and protein. A lentiviral vector carrying the U7.623 gene was effective in restoration of correct splicing in the model cell lines for at least 6 months. Importantly, the therapeutic value of this system was demonstrated in hematopoietic stem cells and erythroid progenitor cells from a patient with IVS2-745/IVS2-1 thalassemia. Twelve days after transduction of the patient cells with the U7.623 lentiviral vector, the levels of correctly spliced beta-globin mRNA and hemoglobin A were approximately 25-fold over background. These results should be regarded as a proof of principle for lentiviral vector-based gene therapy for beta-thalassemia. (literal)
- Prodotto di
- Autore CNR
- Insieme di parole chiave
Incoming links:
- Prodotto
- Autore CNR di
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
- Insieme di parole chiave di